BlueRock Therapeutics Claimed Company
BlueRock Therapeutics LP is a clinical stage cell therapy harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, bemdaneprocel (BRT-DA01) for the treatment of Parkinson’s disease and OpCT-001 for the treatment of primary photoreceptor diseases are clinical stage programs. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves.
read more
Natasha Rathee — SVP, Finance at BlueRock Therapeutics
Executive Bio
Natasha Rathee serves as the SVP, Finance of BlueRock Therapeutics. Natasha Rathee and the BlueRock Therapeutics executive team are rated an A+ by 180 employees.
Executive Team Culture Ratings from BlueRock Therapeutics Employees
TOP
5%
BlueRock Therapeutics' Executive Team scores in the Top 5%
of similar sized companies on Comparably
of similar sized companies on Comparably
BlueRock Therapeutics' Executive Team at a Glance
Based on 357 ratings, BlueRock Therapeutics' employees are very satisfied with their Executive Team and give them an “A+” or 92/100. On average, Women provided higher ratings for their Executive Team compared to Men. Also, the HR department thinks more highly of the Executive Team relative to the Business Development department.
BlueRock Therapeutics' Executive Team ranks in the Top 5% of other companies in Boston and Top 5% of other companies on Comparably that also have 201-500 Employees.
×